Transgenic Research

, Volume 16, Issue 2, pp 147–161 | Cite as

Pharma-Planta: road testing the developing regulatory guidelines for plant-made pharmaceuticals

  • Penelope Amelia Claire Sparrow
  • Judith  A. Irwin
  • Phil J. Dale
  • Richard M. Twyman
  • Julian K. C. Ma
Original Paper

Abstract

Significant advances over the last few years have seen plant-made pharmaceuticals (PMPs) move from the exploratory research phase towards clinical trials, with the first commercial products for human use expected to reach the market by 2009. Europe has yet to witness the commercial application of PMP technology, although at least one product has begun phase II clinical trials with others following close behind. These emerging products are set to challenge the complex and overlapping regulations that currently govern GM plants and ‘conventional’ pharmaceutical production. The areas of responsibility are being mapped out between the different EU regulatory agencies, with specific guidelines currently being drawn up for the regulation of PMPs. This article discusses issues surrounding the development of robust risk-assessment and risk-management practices based on health and environmental impact, while working with EU regulatory authorities to ensure appropriate regulatory oversight.

Keywords

Pharma-Planta PMP Plant made pharmaceuticals Biosafety Regulations 

References

  1. Abell BM, Hahn M, Holbrook LA, Moloney MM (2004) Membrane topology requirements for oil body targeting of oleosin. Plant J 37:461–470PubMedCrossRefGoogle Scholar
  2. Armbruster C, Stiegler GM, Vcelar BA, Jager W, Michael NL, Vetter N, Katinger HW (2002) A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1. AIDS 16:227–33PubMedCrossRefGoogle Scholar
  3. Borisjuk NV, Borisjuk LG, Logendra S, Petersen F, Gleba Y, Raskin I (1999) Production of recombinant proteins in plant root exudates. Nat Biotechnol 17:466–469PubMedCrossRefGoogle Scholar
  4. Claparols MI, Bassies L, Miro B, Del Duca S, Rodriguez-Montesinos J, Christou P, Serafini-Fracassini D, Capell T (2004) Transgenic rice as a vehicle for the production of the industrial enzyme transglutaminase. Trans Res 13:195–199 CrossRefGoogle Scholar
  5. Classen CE (1950) Natural and controlled crossing in Safflower, Carthamus tinctorius L. Agron J 42:381–384CrossRefGoogle Scholar
  6. Coghlan A (2006) Killer tomatoes attack human diseases. New Sci 189:20Google Scholar
  7. Commandeur U, Twyman RM, Fischer R (2003) The biosafety of molecular farming in plants. AgBiotechNet 5:1–9Google Scholar
  8. Doran PM (2000) Foreign protein production in plant tissue cultures. Curr Opin Biotechnol 11:199–204PubMedCrossRefGoogle Scholar
  9. Drake PMW, Chargelegue DM, Vine ND, van Dollweerd JC, Obregon P, Ma JKC (2003) Rhizosecretion of a monoclonal antibody protein complex from transgenic tobacco roots. Plant Mol Biol 52:233–241PubMedCrossRefGoogle Scholar
  10. Dunwell J (2005) Technologies for biological containment of GM and non-GM crops. DEFRA contract CPEC 47Google Scholar
  11. Elbehri A (2005) Biopharming and the food system: examining the potential benefits. AgrBioForum 8:18–25Google Scholar
  12. FDA, CBER, CDER, CFSAN, CDRH, CVM, APHIS, CVB, BRS (2002) Guidance for Industry: drugs, biologics and medical devices derived from bioengineered plants for use in humans and animals. Draft GuidanceGoogle Scholar
  13. Fischer R, Emans N (2000) Molecular farming of pharmaceutical proteins. Trans Res 9:279–299CrossRefGoogle Scholar
  14. Fischer R, Stoger E, Schillberg S, Christou P, Twyman RM (2004) Plant-based production of biopharmaceuticals. Curr Opin Plant Biol 7:152–158 PubMedCrossRefGoogle Scholar
  15. Giddings G, Allison G, Brooks D, Carter A (2000) Transgenic plants as factories for biopharmaceuticals. Nat Biotechnol 18:1151–1155 PubMedCrossRefGoogle Scholar
  16. GM Science Review (2003) First report: an open review of the science relevant to GM crops and food based on the interests and concerns of the publicGoogle Scholar
  17. Gomord V, Sourrouille C, Fitchette AC, Bardor M, Pagny S, Lerouge P, Faye L (2004) Production and glycosylation of plant-made pharmaceuticals: the antibodies as a challenge. Plant Biotechnol J 2:83–100PubMedCrossRefGoogle Scholar
  18. Halsberger AG (2003) Codex guidelines for GM food include the analysis of unintended effects. Nat Biotechnol 21:739–741CrossRefGoogle Scholar
  19. Hellwig S, Drossard J, Twyman RM, Fisher R (2004) Plant cell cultures for the production of recombinant proteins. Nat Biotechnol 22:1415–1422PubMedCrossRefGoogle Scholar
  20. Hoag H (2003) Tougher rules aim to prevent gene flow into crops. Nature 422:103PubMedCrossRefGoogle Scholar
  21. Hood EE, Woodward SL, Horn ME (2002) Monoclonal antibody manufacturing in transgenic plants––myths and realities. Curr Opin Biotechnol 13:630–635 PubMedCrossRefGoogle Scholar
  22. Horn ME, Woodward SL, Howard JA (2004) Plant molecular farming: systems and products. Plant Cell Rep 22:711–720PubMedCrossRefGoogle Scholar
  23. Kapusta J, Modelska A, Figlerowicz M, Pniewski T, Letellier M, Lisowa O, Yusibov V, Koprowski H, Plucienniczak A, Legocki AB (1999) A plant-derived edible vaccine against hepatitis B virus. FASEB J 13:1796–1799PubMedGoogle Scholar
  24. Kormarnytsky S, Borisjuk NV, Borisjuk LG, Alam MZ, Raskin I (2000) Production of recombinant proteins in tobacco guttation fluid. Plant Physiol 124:927–933 CrossRefGoogle Scholar
  25. Kuiper HA, Kleter GA, Noteborn HP, Kok EJ (2001) Assessment of the food safety issues related to genetically modified foods. Plant J 27:503–528PubMedCrossRefGoogle Scholar
  26. Luna SV, Figueroa J, Baltazar M B, Gomez RL, Townsend R, Schoper JB (2001) Maize pollen longevity and distance isolation requirements for effective pollen control. Crop Science 41:1551–1557 CrossRefGoogle Scholar
  27. Ma JKC, Drake PMW, Christou P (2003) The production of recombinant pharmaceuticals in plants. Nat Rev Genet 4: 794–805PubMedCrossRefGoogle Scholar
  28. Ma JKC, Barros E, Bock R, Christou P, Dale PJ, Dix PJ, Fischer R, Irwin J, Mahoney R, Pezzotti M, Schillberg S, Sparrow P, Stoger E, Twyman RM (2005a) Molecular farming for new drugs and vaccines. Current perspectives on the production of pharmaceuticals in transgenic plants. EMBO Rep 6:593–599 CrossRefGoogle Scholar
  29. Ma JKC, Chikwamba R, Sparrow P, Fischer R, Mahoney R, Twyman RM (2005b) Plant-derived pharmaceuticals––The road forward. Trends Plant Sci 10:580–585CrossRefGoogle Scholar
  30. Mäkinen K, Nuutila AM (2004) Barley seed as a production host for industrially important proteins. AgBiotechNet 6:1–8 Google Scholar
  31. Marquet-Blouin E, Bouche FB, Steinmetz A, Muller CP (2003) Neutralising immunogenicity of transgenic carrot (Daucus carota L.) derived measles virus haemagglutinin. Plant Mol Biol 51:459–469PubMedCrossRefGoogle Scholar
  32. Mascia PN, Flavell RB (2004) Safe and acceptable strategies for producing foreign molecules in plants. Curr Opin Plant Biol 7:189–195PubMedCrossRefGoogle Scholar
  33. McGarvey PB, Hammond J, Dienelt MM, Hooper DC, Fu ZF, Dietzschold B, Koprowski H, Michaels FH (1995) Expression of the rabies virus glycoprotein in transgenic tomatoes. Biotechnology 13:1484–1487 PubMedCrossRefGoogle Scholar
  34. Mor TS, Gomez-Lim MA, Palmer KE (1998) Perspective: edible vaccines – a concept coming of age. Trends Microbiol 6:449–453PubMedCrossRefGoogle Scholar
  35. National Research Council (2001) Genetically modified pest- protected plants: science and regulation. National Academy Press, Washington, DC. Google Scholar
  36. Nordlee JA, Taylor SL, Townsend JA, Thomas LA, Bush RK (1996) Identification of a Brazil-nut allergen in transgenic soybeans. New Eng J Med 334(11):688–692PubMedCrossRefGoogle Scholar
  37. Petersen RKD, Arntzen CJ (2004) On risk and plant-based biopharmaceuticals. Trends Biotechnol 22:64–66CrossRefGoogle Scholar
  38. Porceddu A, Falorni A, Ferradini N, Cosentino A, Calcinaro F, Faleri C, Cresti M, Lorenzetti F, Brunetti P, Pezzotti M (1999) Transgenic plants expressing human glutamic acid decarboxylase (GAD 65), a major autoantigen in insulin-dependent diabetes mellitus. Mol Breeding 5:553–560CrossRefGoogle Scholar
  39. Pujol M, Ramirez NI, Ayala M, Gavilondo JV, Valdes R, Rodriguez M, Brito J, Padilla S, Gomez L, Reyes B, Peral R, Perez M, Marcelo JL, Mila L, Sanchez RR, Paez R, Cremata JA, Enriquez G, Mendoza O, Ortega M, Borroto C (2005) An integral approach towards a practical application for a plant-made monoclonal antibody in vaccine purification. Vaccine 23:1833–1837PubMedCrossRefGoogle Scholar
  40. Ramirez N, Rodriguez M,Ayala M,Cremata J, Pérez M,Martinez A, Linares M,HeviaY,Páez R, Valdés R, Gavilondo JV, Selman-Housein G (2003) Expression and characterisation of an anti-(hepatitis B surface antigen) glycosylated antibody in transgenic tobacco (Nicotiana tabacum) plants and its use in the immunopurification of its target antigen. Biotechnol Appl Biochem 38:223–230PubMedCrossRefGoogle Scholar
  41. Ritala A, Nuutila AM, aikasalo R, Kauppinen V, Tammisola J (2002) Measuring gene flow in the cultivation of transgenic barley. Crop Sci 42:278–285PubMedCrossRefGoogle Scholar
  42. Sala F, Rigano MM, Barbante A, Basso B, Walmsely AM, Castiglioni S (2003) Vaccine antigen production in transgenic plants: strategies, gene constructs and perspectives. Vaccine 21:803–808PubMedCrossRefGoogle Scholar
  43. Sandhu JS, Rasnyanski SF, Domier LL, Korban SS, Osadjan MD, Buetow DE (2000) Oral immunisation of mice with transgenic tomato fruit expressing respiratory syncytial virus-F protein induces a systemic immune response. Trans Res 9:127–135CrossRefGoogle Scholar
  44. SemBioSys (2003) Oil bodies and associated proteins as affinity matricies. US patent 6509453Google Scholar
  45. Smyth S, Phillips PWB (2002) Production differentiation alternatives: Identity preservation, segregation and traceability. AgBioForum 5:30–42Google Scholar
  46. Stoger E, Ma JK-C, Fischer R, Christou P (2005) Sowing the seeds of success: pharmaceutical proteins from plants. Curr Opin Biotechnol 16:167–173PubMedCrossRefGoogle Scholar
  47. Stoger E, Sack M, Fischer R, Christou P (2002 ) Plantibodies: applications, advantages and bottlenecks. Curr Opin Biotechnol 13:161–166PubMedCrossRefGoogle Scholar
  48. Streatfield SJ, Howard JA (2003) Plant-based vaccines. Int J Parasitol 33:479–493PubMedCrossRefGoogle Scholar
  49. Tackaberry ES, Prior F, Bell M, Tocchi M, Porter S, Mehic J, Ganz PR, Sardana R, Altosaar I, Dudani A (2003) Increased yield of heterologous viral glycoprotein in the seeds of homozygous tobacco plants cultivated underground. Genome 46:521–526PubMedCrossRefGoogle Scholar
  50. Tekoah Y, Ko K, Koprowski H, Harvey DJ, Wormald MR, Dwek RA, Rudd PM (2004) Controlled glycosylation of therapeutic antibodies in plants. Arch Biochem Biophys 426:266–278PubMedCrossRefGoogle Scholar
  51. The Royal Society of Canada (2001) Elements of precaution: recommendations for the regulation of food biotechnology in Canada. Google Scholar
  52. Twyman RM, Schillberg S, Fischer R (2005) The transgenic plant market in the pharmaceutical industry. Expert Opin Emerg Drugs 10:185–218PubMedCrossRefGoogle Scholar
  53. Twyman RM, Stoger E, Schillberg S, Christou P, Fischer R (2003) Molecular farming in plants: host systems and expression technology. Trends Biotechnol 21:570–577PubMedCrossRefGoogle Scholar
  54. Valdés R, Gómez L, Padilla S, Brito J, Reyes B, Álvarez T, Mendoza O, Herrera O, Ferro W, Pujol M,Leal V, Linares M, Hevia Y, Garcí Mila L, García O, Sánchez R, Acosta A, Geada D, Paez R Vega JL, Borroto C (2003) Large-scale purification of an antibody directed against hepatitis B surface antigen from transgenic tobacco plants. Biochem Biophys Res Commun 308:94–100 PubMedCrossRefGoogle Scholar
  55. Walmsley AM, Arntzen CJ (2003) Plant cell factories and mucosal vaccines. Curr Opin Biotechnol 14:145–150PubMedCrossRefGoogle Scholar
  56. Walmsley AM, Alvarez ML, Jin Y, Kirk DD, Lee SM, Pinkhasov J, Rigano MM, Arntzen CJ, Mason HS (2003) Expression of the B subunit of Escherichia coli heat labile enterotoxin as a fusion protein in transgenic tomato. Plant Cell Rep 21:1020–1026PubMedCrossRefGoogle Scholar
  57. Wang LJ, Ni DA, Chen YN, Lee ZM (2001) The expression of Mycobacterium tuberculosis MPT64 protein in transgenic carrots. Acta Bot Sin 43:132–137CrossRefGoogle Scholar
  58. Yang D, Guo F, Huang N, Watkins S (2003) Expression and localisation of human lysozyme in the endosperm of transgenic rice. Planta 216:597–603PubMedGoogle Scholar
  59. Yusibov V, Hooper DC, Spitsin S, Fleysh N, Kean RB, Mikheeva T, Deka D, Karasev A, Cox S, Randall J, Koprowski H (2002) Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine. Vaccine 20:3155–3164PubMedCrossRefGoogle Scholar
  60. Zeitlin L, Olmsted SS, Moench TR, Co MS, Martinell BJ, Paradkar VM, Russell DR, Queen C, Cone RA, Whaley KJ (1998) A humanized monoclonal antibody produced in transgenic plants for immunoprotection of the vagina against genital herpes. Nat Biotechnol 16:1361–1364Google Scholar

Copyright information

© Springer Science+Business Media B.V. 2007

Authors and Affiliations

  • Penelope Amelia Claire Sparrow
    • 1
  • Judith  A. Irwin
    • 1
  • Phil J. Dale
    • 2
  • Richard M. Twyman
    • 3
  • Julian K. C. Ma
    • 4
  1. 1.John Innes CentreNorwich Research ParkNorwichUK
  2. 2.Emeritus Fellow, John Innes CentreNorwich Research ParkNorwichUK
  3. 3.Department of BiologyUniversity of YorkHeslington, YorkUK
  4. 4.St George’s Hospital Medical SchoolUniversity of LondonLondonUK

Personalised recommendations